TargetMol

Ramosetron hydrochloride

Product Code:
 
TAR-T4562L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T4562L-10mg10mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4562L-25mg25mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4562L-50mg50mg£152.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4562L-100mg100mg£214.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4562L-200mg200mg£287.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ramosetron hydrochloride is a serotonin 5-HT3 receptor antagonist. It is used to treat diarrhea-predominant irritable bowel syndrome and nausea.
CAS:
132907-72-3
Formula:
C17H18ClN3O
Molecular Weight:
315.8
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9996
SMILES:
Cl.Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12
Target:
5-HT Receptor

References

Kim TK, Cho YJ, Lim CW, Min JJ, Choi EK, Hong DM, Jeon Y. Effect of ramosetron on QTc interval: a randomised controlled trial in patients undergoing off-pump coronary artery bypass surgery. BMC Anesthesiol. 2016 Aug 3;16(1):56. doi: 10.1186/s12871-016-0222-1. PubMed PMID: 27488394; PubMed Central PMCID: PMC4972982. Lee YH, Seo JH, Min KT, Lim YJ, Jeong SW, Lee EK, Choi BM, Noh GJ. Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients. Br J Clin Pharmacol. 2016 Sep;82(3):762-72. doi: 10.1111/bcp.13010. Epub 2016 Jun 8. PubMed PMID: 27195435. Song HJ, Seo HJ, Son H. Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2016 Aug 15. [Epub ahead of print] Review. PubMed PMID: 27526189. Joo J, Park S, Park HJ, Shin SY. Ramosetron versus ondansetron for postoperative nausea and vomiting in strabismus surgery patients. BMC Anesthesiol. 2016 Jul 22;16(1):41. doi: 10.1186/s12871-016-0210-5. PubMed PMID: 27449404; PubMed Central PMCID: PMC4957928.